Randomised, controlled, 48-week study of switching stavudine and/or protease inhibitors to Combavir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients
John, M., McKinnon, E.J., James, I.R., Nolan, D., Herrmann, S.E., Moore, C.B., White, A.J. and Mallal, S.A. (2003) Randomised, controlled, 48-week study of switching stavudine and/or protease inhibitors to Combavir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. JAIDS Journal of Acquired Immune Deficiency Syndromes, 33 (1). pp. 29-34.
*Subscription may be required
Objective: HIV-1 protease inhibitors (versus no protease inhibitors) and stavudine (versus zidovudine) are independently associated with a higher risk of lipoatrophy in HIV-infected patients. We sought to determine whether the revision of stavudine and/or protease inhibitor-containing regimens to combivir/abacavir would result in prevention and/or reversibility of lipoatrophy in HIV-1-infected patients.
Design: The investigation was a prospective, randomized, controlled, open-label study.
Subjects: The subjects included 37 HIV-1-infected individuals with stable undetectable HIV-1 loads who were taking a regimen containing either stavudine or zidovudine with lamivudine and a protease inhibitor.
Intervention: Subjects were randomized to continue therapy or switch stavudine to zidovudine and protease inhibitor to abacavir, such that the universal switch regimen was combivir (zidovudine/lamivudine) and abacavir.
Main Outcome Measures: Total body, leg, and arm fat mass was measured at baseline, 24 weeks, and 48 weeks using whole-body dual-energy x-ray absorptiometry. Single-cut L4 computed tomography and assays of multiple metabolic parameters were also performed.
Results: There was an average gain in fat mass of 0.009 kg/(leg[middle dot]mo) in switch patients versus a loss of 0.010 kg/(leg[middle dot]mo) in controls (p = .04, on-treatment analysis) over 48 weeks. Significant arm fat restoration was observed in patients who switched regimens, with an average gain of 0.014 kg/(arm[middle dot]mo) (p = .004), whereas controls did not have a significant change from baseline. Analyses of percentage changes in arm and leg fat masses showed similar findings. No significant effects on intra-abdominal fat, blood lipid levels, glycemic indices, and lactate levels were detected, although most baseline mean values were normal in study subjects. Combivir/abacavir maintained virological control in all but one case, and three (13.6%) of 22 individuals had adverse reactions to abacavir therapy.
Conclusions: A switch to combivir/abacavir therapy was associated with objective evidence of limb fat-sparing and fat restoration compared with continued treatment with stavudine and/or protease inhibitor.
|Publication Type:||Journal Article|
|Murdoch Affiliation:||Centre for Clinical Immunology and Biomedical Statistics|
|Publisher:||Lippincott Williams & Wilkins|
|Copyright:||(C) 2003 Lippincott Williams & Wilkins, Inc.|
|Item Control Page|